Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:40 AM
Ignite Modification Date:
2025-12-25 @ 12:40 AM
NCT ID:
NCT02483767
Eligibility Criteria:
Inclusion Criteria:
* The patients signed the written informed consent.
* Histologically proven stage I, II, or III breast cancer
* Must be candidates for adjuvant or neoadjuvant chemotherapy,
* Must be premenopausal.
* Trastuzumab is permitted in patients with human epidermal growth factor receptor 2 (HER2) overexpressing tumors.
Exclusion Criteria:
* The patients were previous chemotherapy;
* Evidence of distant metastases;
* Other malignancies in the previous 5 years.
* The patients were using GnRHa, progesterone, stimulate ovulation drugs, oral contraceptives, aromatase inhibitors, intrauterine device with hormone, subcutaneous preparations contraceptive drugs such as hormone drugs and instruments during 3 month preceding the start of chemotherapy.
* Pregnancy or lactation.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
45 Years
Study:
NCT02483767
Study Brief:
Protocol Section:
NCT02483767